Latest From Ceremed Inc.
Medtronic's INFUSE bone morphogenetic protein is the only product in the musculoskeletal industry that has changed the bar in terms of bone healing, and it is under fire for complications related to off-label use. As regulators and payors crack down on INFUSE and hospitals restrict access to the product, surgeons are seeking alternatives and there are a number of companies lining up to fill the void
- Implantable Devices
- Therapeutic Areas
- Blood & Coagulation Disorders & Products
- Musculoskeletal & Connective Tissue Disorders
- North America
- Parent & Subsidiaries
- Ceremed Inc.
- Senior Management
Tadeusz Wellisz, Pres. & CEO
Anthony Ruggiero, VP, Sales & Bus. Dev.
- Contact Info
Phone: (310) 815-2125
3643 Lenawee Ave.
Los Angeles, CA 90016
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.